R agonist), or vehicle. In separate groups of animals, the effects of pertussis toxin, forskolin, glibenclamide, 4-aminopyridine, tetraethylammonium, apamin, charybdotoxin, or margatoxin on R-PIA-induced antinociception were examined.
ADENOSINE, an important endogenous modulator of neurotransmission, inhibits synaptic transmission in the central nervous system [1] [2] [3] and is involved in the regulation of several biologic functions, including anxiety, cognition, and memory, mediating its actions by stimulation of adenosine A 1 , A 2a , A 2b , and A 3 G protein-coupled receptors. There is now ample evidence that activation of spinal A 1 adenosine receptors (A 1 Rs), present in su-perficial layers of the dorsal spinal cord and on afferent terminals of nociceptors, 4 causes antinociception after nerve injury or inflammation and decreases C fiberdriven responses in dorsal horn neurons. 5 Mice lacking A 1 Rs exhibited increased nociceptive responses. 6, 7 However, the exact mechanisms by which A 1 Rs agonists cause antinociception remain to be defined. Patel et al. 8 demonstrated that activation of A 1 Rs hyperpolarizes spinal dorsal horn neurons by increasing potassium conductance, resulting in postsynaptic inhibition of excitatory transmission. Furthermore, the inhibitory action of adenosine in the spinal cord may be caused by activation of presynaptic A 1 Rs present on sensory afferent terminals and dorsal root ganglion neurons, leading to a decrease in cyclic adenosine monophosphate (cAMP) production and an inhibition of excitatory neurotransmitter release. 1, 2 In contrast, the role of the spinal A 2a adenosine receptor (A 2a R), most likely present on spinal presynaptic terminals of sensory afferents, 9, 10 for pain transmission is uncertain. 8, 11 In a recent study, Yoon et al. 12 demonstrated that intrathecal administration of the A 2a R agonist 2-w p-2-carbonyl-ethyl-phenylethylaminox-5X-N-ethylcarboxami-doadenosine (CGS21680) inhibited both phases of formalin-induced pain behaviors. Only a modest antinociceptive effect of spinally administered CGS21680 was observed for inflammation-induced hyperalgesia. 13 In contrast, mice lacking the adenosine A 2a R were hypoalgesic, 14 and A 2a R antagonists produced antinociception, 15 indicating that A 2a Rs mediate pronociceptive effects. Other investigators did not observe any role of spinal A 2a Rs for nociceptive modulation. 2, 11 A common form of acute pain and hyperalgesia in humans is postoperative pain. To reduce pain in the perioperative period and improve patients outcome, new treatment strategies must be developed. There is now plenty of evidence that postoperative pain is based on distinct pathophysiologic and pharmacologic mechanisms compared with other pain models. 16 -18 We hypothesize that A 1 R but not A 2a R activation modifies pain behaviors caused by an incision. Furthermore, we assumed that A 1 R-induced antinociception may be mediated by different mechanisms, including the activation of pertussis toxin (PTX)-sensitive G proteins or different potassium channels. Therefore, the aim of the current study was to investigate the role of spinal adenosine A 1 R and A 2a R for the maintenance of spontaneous nonevoked pain behavior and evoked mechanical hyper-algesia after a surgical incision by using a rat model for postoperative pain. 19 In addition, we sought to examine possible mechanisms of adenosine A 1 receptor-induced antinociception after incision.
Materials and Methods

General
These experiments were reviewed and approved by the Institution's Animal Care and Use Committee in Muenster, Germany. The animals were treated in accordance with the Ethical Guidelines for Investigations of Experimental Pain in Conscious Animals as issued by the International Association for the Study of Pain. 20 Experiments were performed in 135 adult (weight, 280 -350 g) male Sprague-Dawley rats (Harlan, Indianapolis, IN) housed in pairs before surgery. All persons performing experiments were blinded to the drug administered. Food and water were available ad libitum. Postoperatively, the animals were housed individually. Eight animals were excluded for wound dehiscence or clotted catheters; at the end of the protocol, all animals were anesthetized and killed with an overdose of potassium chloride administered intracardially.
Surgery
For subarachnoid drug administration, a lumbar intrathecal catheter was placed using a technique 21 modified from one described previously. 22 Briefly, after isoflurane anesthesia, the lumbar skin was cleansed and incised. The intervertebral space between L5 and L6 was punctured with a hypodermic needle, and a 32-gauge polyurethane catheter (length 10 cm, 32-PU, OD 0.010 inches, ID 0.005 inches; Micor, Allison Park, PA) was advanced through the needle in the lumbar area of the spinal cord. The distal end was secured, inserted into PE-10 tubing, and tunnelled to the cervical region. The catheter (8 l dead space) was flushed with saline and sealed. One day after catheter placement, 20 l lidocaine, 2%, was administered, and only rats with a brief bilateral hind limb paresis were studied. Experiments were begun not less than 3 days after intrathecal catheter placement. At the end of the experiment, the localization of the catheter was verified by injecting 30 l methylene blue, killing the rat, and dissecting the lumbar spinal cord. In rats with a functional intrathecal catheter, segments of the lumbar spinal cord were dyed with methylene blue.
For paw incisions, all rats were anesthetized with 1.5-2% isoflurane delivered via a nose cone. As described previously, 19 a 1-cm longitudinal incision was made through skin and fascia of the plantar aspect of the right hind paw including the plantaris muscle. The skin was apposed with two mattress sutures of 5-0 nylon. After surgery, the animals were allowed to recover in their cages. Sutures were removed approximately 30 h later at the end of postoperative day 1, and the wounds healed well within 5-6 days. The animals did not receive additional analgesics after surgical treatments such as catheter placement or paw incision.
Pain Behaviors
On the day of the experiment, the rats were placed individually on an elevated plastic mesh floor. After adaptation to testing conditions, baseline nonevoked or evoked pain behaviors before paw incision were measured as described. 19, 23 Nonevoked (spontaneous) pain behaviors were assessed by a cumulative pain score as described previously. 23, 24 Unrestrained rats were placed on a plastic mesh floor, and the incised foot of each animal was closely observed during a 2.5-min period for 30 min. Depending on the position in which the foot was found during the majority of the 2.5-min scoring period, a 0, 1, or 2 was given. Full weight bearing of the foot (score ϭ 0) was present if the wound was blanched or distorted by the mesh. If the foot was completely off the mesh, a score of 2 was recorded. If the area of the wound touched the mesh without blanching or distorting, a 1 was given. The sum of the 12 scores (0 -24) obtained during the 30-min session for the incised foot was obtained.
Withdrawal responses to punctate mechanical stimulation (evoked pain behavior) were determined using calibrated nylon von Frey monofilaments applied from underneath the cage through openings (12 ϫ 12 mm) in the plastic mesh floor to an area adjacent to the wound. Each von Frey filament was applied once starting with 15 mN and continuing until a withdrawal response occurred or 247 mN (the cutoff value) was reached. The median of the lowest force from the three tests producing a response was considered the withdrawal threshold. For this study, 563 mN was recorded as the withdrawal threshold if there was no withdrawal response to the next lowest filament (247 mN). However, using standard von Frey filaments to assess mechanical pain thresholds has several limitations. Most importantly, shape and size of the filaments are critical factors for mechanical pain perception. Von Frey filaments with flat ends bend on the skin at their sharp corners, and different probe angles may cause variable mechanical thresholds. Greenspan et al. 25, 26 reported that a change in probe angle of 15°produced variable pain thresholds with a stimulus of the same tip size. Furthermore, different von Frey filament strengths vary in their tip diameters up to 100-fold, indicating that there is a trade-off between the force applied and the probe circumference for pain threshold. In addition, Hogan et al. 27 further indicate that decreased withdrawal thresholds caused by a peripheral nerve injury assessed by von Frey filaments are not valid measures for neuropathic pain. However, we speculate that this is different to acute postoperative pain. In contrast to neuropathic pain, a surgical incision causes robust mechanical hyperalgesia characterized by decreased withdrawal thresholds to von Frey filaments; mechanical hyperalgesia was blocked by morphine or other analgesics. Therefore, we suggest that besides the limitations of standard von Frey filaments, mechanical hyperalgesia is a robust and important feature of postoperative pain.
Experimental Protocols Experiment 1: Effects of A 1 R and A 2a R Agonists on Nonevoked Pain
Behavior. Twenty-one rats were pretested for nonevoked pain behaviors as described in the first two paragraphs of the Pain Behaviors section. The incision was made in the plantar aspect of the foot, and after a recovery time of 2 h, spontaneous pain behavior was assessed.
Subsequently, 5 nmol R-phenylisopropyl-adenosine (R-PIA; adenosine A 1 receptor agonist), 10 nmol CGS21680, or vehicle was administered intrathecally (n ϭ 6 -8/ group). Nonevoked pain behavior was measured every 30 min after drug injection for the next 3 h on the day of surgery and postoperative day 1.
Experiment 2: Evaluating Effects of A 1 R and A 2a R Agonists on Evoked Mechanical Hyperalgesia after
Incision. Twenty-eight rats were pretested for mechanical withdrawal threshold as described above. The incision was made in the plantar aspect of the foot, and after a recovery time of 2 h, responses to mechanical stimuli were tested. Subsequently, 0.3, 1, or 5 nmol R-PIA (adenosine A 1 receptor agonist) or vehicle was administered intrathecally (n ϭ 6 -8/group). Mechanical hyperalgesia was measured at 30 and 60 min and then every hour after drug injection for the next 5 h. In separate groups of animals, administration of an A 1 R antagonist (CPT, 242 nmol) or an A 2a R antagonist (DMPX, 50 nmol) was followed by 5 nmol R-PIA (n ϭ 4).
In another group of rats, 2, 10, or 20 nmol CGS21680 (adenosine A 2a receptor agonist) or vehicle was administered intrathecally (n ϭ 6 -8/group). Mechanical hyperalgesia was measured at 30 and 60 min and then every hour after drug injection for the next 5 h. In separate groups of animals, administration of an A 1 R (CPT, 242 nmol) or A 2 R antagonist (DMPX, 50 nmol) was followed by 20 nmol CGS21680 (n ϭ 4).
Experiment 3: Evaluating Mechanisms of A 1 R-induced Antinociception.
In a separate experiment, rats were pretreated with 0.5 g PTX 7 days before incision. A greater effect of the toxin at 6 days compared with 2 days to disrupt the inhibitory secondary messenger pathway has been observed. 28 In the current study, PTXpretreated rats were tested before and 2 h after incision, with observation of similar mechanical thresholds compared with untreated animals, indicating that 0.5 g PTX did not affect pain behaviors on its own. In agreement, other investigators demonstrated that low PTX doses (0.5-1 g) did not produce pain behavior in uninjured animals. 28, 29 On the day of surgery, 5 nmol R-PIA was administered after incision, and mechanical hyperalgesia was measured at 30 and 60 min and then every hour after drug injection for the next 5 h (n ϭ 6). In another group of animals, 5 nmol R-PIA was injected in rats pretreated with 10 g forskolin, and mechanical hyperalgesia was assessed for 5 h (n ϭ 5). Similar forskolin doses were used by other investigators without showing pain behavior in uninjured animals. 30 In another group of animals, 5 nmol R-PIA was administered after pretreatment with vehicle or 20, 50 or 100 nmol of the adenosine triphosphate-sensitive potassium (K ATP ) channel blocker glibenclamide (n ϭ 6 -8/group) or after pretreatment with the nonselective potassium channel blockers 4-aminopyridine (4-AP; n ϭ 5; 5 nmol) and tetraethylammonium (n ϭ 5; 100 nmol); mechanical hyperalgesia was assessed for 5 h as described above. Doses for tetraethylammonium and 4-AP were evaluated by a dose finding experiment. Greater doses of tetraethylammonium and 4-AP cause significant adverse effects, including intense pain behaviors or motor impairment.
In a separate group of animals, R-PIA was administered 10 -15 min after intrathecal administration of apamin (n ϭ 4; 3 ng), charybdotoxin (n ϭ 4; 1 ng), or margatoxin (n ϭ 6; 10 ng), and pain behaviors were assessed. None of these selective potassium channel blockers alone produced pain behaviors. 31
Drugs
All drugs were purchased from Sigma (Hamburg, Germany) or Tocris (Bristol, United Kingdom). To enhance their solubility, R-PIA (0.3-10 nmol, A 1 R agonist; Ki A 1 / A 2a : 2/860 nM) 32 was dissolved in a pH-adjusted HCl solution, and CGS21680 (2-20 nmol, A 2a R agonist; Ki A 1 /A 2a : 2,600/15 nM) 13 was dissolved in a pH-adjusted NaOH solution. The pH of all drugs and vehicles administered was 7.0 -8.4. CPT (A 1 R antagonist, 242 nmol; Ki A 1 /A 2a : 10.9/1,440 nM), 13 DMPX (A 2a antagonist, 50 nmol; Ki A 1 /A 2a : 1,200/8.2 nM), 33 tetraethylammonium (nonselective potassium channel blocker, 100 nmol), 4-AP (nonselective potassium channel blocker, 5 nmol), PTX (0.5 g), 28, 30 apamin (small-conductance calciumactivated potassium channel inhibitor, Kd: 60 pM-100 nM; 3 ng), 34 charybdotoxin (large-and intermediate-conductance calcium-activated potassium channel blocker, Kd: 1.7-5 nM, voltage-gated potassium channel inhibitor 1.3, Kd: 0.17 nM, 1 ng), 31 and margatoxin (voltage-gated potassium channel inhibitor Kv1.3 and Kv1.6; Kd: 0.03 and 5 nM; 10 ng) 31 were dissolved in saline; forskolin (cAMP activator, 10 g) 30 was dissolved in 10% ethanol, and glibenclamide (K ATP channel inhibitor, 10 -100 nmol) 35 was dissolved in 50% dimethyl sulfoxide. Peng et al. 36 demonstrated that up to 50% of dimethyl sulfoxide did not change the activity of dorsal horn neurons, and greater doses of dimethyl sulfoxide were administered intrathecally in in vivo experiments by others. 31 Intrathecal injection volumes for all substances were 10 l followed by a 10-l flush of preservative-free saline. All drugs were prepared on the day of the experiment.
Statistical Analysis
The results are presented as median for ordinal data, and all data were compared using nonparametric analyses. The Friedman test for within-group comparisons and the Kruskal-Wallis test and Wilcoxon-Mann-Whitney test for between-groups comparisons were used. Multiple comparisons after the Friedman test and Kruskal-Wallis test were performed using a Dunnett test or Dunn test for nonparametric analysis. 37 P Ͻ 0.05 was considered significant.
Results
Experiment 1: Effects of A 1 R and A 2a R Agonists on Nonevoked Pain Behavior
In all groups of animals, similar nonevoked pain behavior 2 h after surgery was observed (figs. 1A-C). Intrathecal administration of R-PIA (5 nmol) but not of CGS21680 (10 nmol) produced a decrease of the median pain score from 18.5 (0 h) to 7 during the first hour after drug administration (P Ͻ 0.05 vs. 0 min; figs. 1B and C). Decreased nonevoked pain behaviors lasted for more than 2 h. The next day, baseline pain scores were assessed, and similar results were obtained (P Ͻ 0.05 vs. 0 min; fig. 1D ).
Experiment 2: Evaluating Effects of A 1 R and A 2a R Agonists on Evoked Mechanical Hyperalgesia after Incision
In vehicle-treated rats, the median withdrawal threshold to von Frey filaments decreased from 563 mN (pre) before surgery to 36.9 mN 2 h (0 min before intrathecal drug administration) after incision. Hyperalgesia was persistent; median withdrawal thresholds were 36.9 mN or less throughout the day of surgery ( fig. 2A ). Intrathecal administration of 0.3, 1, and 5 nmol R-PIA produced a dose-dependent increase of the reduced withdrawal thresholds after incision for 30 and 60 min, respectively (P Ͻ 0.05 vs. 0 min; figs. 2B-D), indicating an A 1 Rinduced reduction of hyperalgesia. Intrathecal pretreatment with CPT (242 nmol), a specific A 1 R antagonist, but not with DMPX (50 nmol), a specific A 2a R antagonist, blocked R-PIA (5 nmol)-induced antinociception (figs. 2E and F). Similar results were observed on postoperative day 1 (fig. 2G ).
In separate groups of animals, intrathecal administration of a vehicle or 2 or 10 nmol CGS21680 did not modify pain behaviors (figs. 3A-C), but intrathecal injection of 20 nmol CGS21680 caused a brief increase in withdrawal thresholds 30 min after injection (P Ͻ 0.05 vs. 0 min; fig. 3D ). This short-lasting antihyperalgesic effect was blocked by intrathecal pretreatment with CPT (A 1 R antagonist) but not with the corresponding A 2a R antagonist DMPX, indicating that the CGS21680-induced increase of withdrawal thresholds was due to an unspecific activation of the A 1 R (figs. 3E and F). Similar results were observed on postoperative day 1 ( fig. 3G ).
Experiment 3: Evaluating Mechanisms of A 1 R-induced Antinociception
Intrathecal pretreatment with 0.5 g PTX 7days before administration of 5 nmol R-PIA blocked R-PIA-induced increase of withdrawal thresholds ( fig. 4A ). Similarly, in rats pretreated with forskolin, the subsequent intrathecal administration of R-PIA did not modify mechanical withdrawal thresholds after incision ( fig. 4B ). In addition, pretreatment of PTX or forskolin followed by a vehicle injection (data not shown) did not increase hyperalgesia in rats after an incision, indicating that the inhibition of R-PIA-induced antinociception by PTX or forskolin pretreatment was not caused by a baseline shift of withdrawal thresholds.
Intrathecal pretreatment with the nonselective potassium blocker tetraethylammonium (100 nmol) or 4-AP (5 nmol) reduced R-PIA-induced antinociception, indicating that potassium channels were involved in this process (P Ͻ 0.05 vs. 0 min; figs. 5A and B). Intrathecal pretreatment with glibenclamide produced a dose-dependent inhibition of R-PIA-induced antinociception (P Ͻ 0.05 vs. 0 min; figs. 5C-F). Intrathecal administration of glibenclamide (100 nmol) and subsequent vehicle did not modify persistent hyperalgesia after incision (data not shown). Intrathecal administration of neither apamin nor charybdotoxin modified hypoalgesia mediated by R-PIA (P Ͻ 0.05 vs. 0 min; figs. 6A and B); a small but not statistically significant inhibition of R-PIA-induced hypoalgesia was observed with a pretreatment of margatoxin (P Ͻ 0.05 vs. 0 min; fig. 6C ). Higher intrathecal doses of apamin, charybdotoxin, or margatoxin produced severe pain behaviors and were not used in this study. Therefore, K ATP channels but not calcium-activated potassium channels and the voltage-gated potassium channels Kv1.3 and Kv1.6 are partially involved in A 1 R-induced antinociception.
Discussion
In the current study, we demonstrated that the intrathecal administration of an A 1 R agonist (R-PIA) but not of an A 2a R agonist (CGS21680) decreased nonevoked pain behaviors and evoked mechanical hyperalgesia after a surgical incision. Furthermore, A 1 R-induced spinal antinociception is mediated by interactions with PTX-sensitive G proteins and due to the inhibition of adenylate 
. Effect of intrathecal A 1 adenosine receptor agonist R-PIA on punctuate mechanical hyperalgesia caused by incision. The results for mechanical hyperalgesia are expressed as median (horizontal line) with 1st and 3rd quartiles (boxes). (A-D) Withdrawal threshold after incision in rats treated with vehicle or 0.3, 1, or 5 nmol of the A 1 adenosine receptor agonist R-PIA. (E and F) Blockade of the antihyperalgesic effect of 5 nmol R-PIA by intrathecal administration of the A 1 adenosine receptor antagonist CPT but not by the A 2a adenosine receptor antagonist DMPX. (G) Summary of withdrawal thresholds 30 min after administration of vehicle or different doses of R-PIA. * P < 0.05 versus 0 min by Friedman and Dunnett test. † versus vehicle by Kruskal-Wallis and Dunn test.
cyclase. In addition, the opening of K ATP channels but not of calcium-activated potassium channels or Kv1.3 or 1.6 channels contribute to the antinociceptive effect of adenosine receptor agonists.
Effect of Spinal A 1 and A 2a Adenosine Receptor Agonists on Hyperalgesia in Animal Models
Several investigators have examined the effects of spinally administered A 1 R agonists in models of persistent pain and hyperalgesia. In vitro and in vivo electrophysiologic experiments demonstrated that activation of A 1 Rs hyperpolarize dorsal horn neurons in lamina II and inhibit the C fiber-induced windup phenomenon. 5, 8, 11, 38 Intrathecal administration of selective A 1 R agonists reduced pain behaviors after chemical irritation, 12 nerve injury, 32, 39 spinal cord injury, 40 and inflammation. 13 Furthermore, mice lacking the A 1 R exhibited increased nociceptive responses under normal conditions and enhanced heat hyperalgesia after inflammation and nerve injury. 6, 7 In agreement, results from the current study revealed that spinal administration of an A 1 R agonist decreased dose dependently mechanical hyperalgesia after an incision, indicating that activation of the A 1 R affects the maintenance of exaggerated pain behaviors in this model for postoperative pain. Accordingly, previous experiments demonstrated a dose-dependent antihyper- sensitivity effect of the positive allosteric adenosine receptor modulator T62 after intrathecal administration in the incisional model for postoperative pain. 18, 41 In contrast, the role of the spinal A 2a R for pain processing is uncertain. 8, 11 Recently, Yoon et al. 12 demonstrated that intrathecal administration of the A 2a R agonist DPMA inhibited both phases of formalin-induced pain behaviors. Poon et al. 13 revealed only a modest antinociceptive effect of the spinally administered A 2a R agonist CGS21680 on inflammation-induced thermal hyperalgesia, arguing that this might be due to an unspecific activation of A 1 Rs. However, other investigators did not observe antinociceptive effects after spinal A 2a R activation. In electrophysiologic studies of spinal cord slices, application of CGS21680 (A 2a R agonist) was without effects on neuronal transmission 11 or exhibited a mix of excitatory and inhibitory effects. 2, 8 In the current study, intrathecal administration of CGS21680 did not decrease mechanical hyperalgesia after incision. Moderate effects on incision-induced hyperalgesia after application of higher doses of CGS21680 were due to an unspecific activation of A 1 Rs and therefore blocked by an A 1 R antagonist but not by an A 2a R antagonist.
Fig. 3. Effect of intrathecal A 2a adenosine receptor agonist CGS21680 on punctuate mechanical hyperalgesia caused by incision. (A-D) Withdrawal threshold after incision in rats treated with vehicle or 2, 10, or 20 nmol of the A 2a adenosine receptor agonist CGS21680. (E and F) Blockade of the antihyperalgesic effect of 20 nmol CGS21680 by intrathecal administration of the noncorresponding A 1 adenosine receptor antagonist CPT but not by the corresponding A 2a adenosine receptor antagonist DMPX, indicating an unspecific
Possible Mechanisms of A 1 R-induced Antinociception: Role of PTX-sensitive Inhibitory G Proteins
Although there is ample evidence that adenosine-induced spinal antinociception is largely mediated by ac- tivation of A 1 Rs, little is known about the underlying mechanisms. A 1 Rs are coupled to PTX-sensitive Gi proteins reducing cAMP levels by inhibiting adenylyl cyclase. 2 Because increased cAMP levels facilitate the release of neurotransmitters, 42 enhance the excitability of dorsal horn neurons or spinothalamic tract cells, 43 and result in hyperalgesia, 44 it has been suggested that modifying the cAMP transduction cascade represents one downstream mechanism by which activation of A 1 Rs produces antinociception. 45 In agreement, presynaptic A 1 Rs located on sensory afferent terminals and dorsal root ganglion neurons decreased cAMP production 1,2 and inhibited the release of neurotransmitters such as CGRP 46 and glutamate. 47, 48 Furthermore, a decrease of spinal glutamate release caused by presynaptic A 1 R activation was observed after capsaicin injection and nerve injury 47, 48 but not after formalin injection, 49 indicating that characteristic mechanisms of A 1 R activation occur after different types of tissue injuries. Although not investigated in the current study, we speculate that activation of presynaptic A 1 Rs is crucial for A 1 R-induced antinociception.
Pertussis toxin ribosylates the ␣ subunit of inhibitory G proteins linked to adenylate cyclase and disrupt this inhibitory secondary messenger pathway, leading to increased levels of cAMP. 50 Previous studies demonstrated that PTX prevented A 1 R-mediated inhibition of adenylate cyclase 50 and reduced effects of A 1 R agonists on normal nociception in uninjured animals. 30 In the current study, pretreatment with PTX inhibited the hypoalgesic effect of intrathecal R-PIA, implicating that A 1 R-induced spinal antinociception is mediated by interactions with PTX-sensitive inhibitory Gi proteins. In addition, we demonstrated that a brief pretreatment with forskolin attenuated the hypoalgesic effect of intrathecal R-PIA, suggesting that the cAMP transduction cascade is involved in A 1 R-induced antinociception. Accordingly, several lines of evidence demonstrated that spinal PTX-sensitive G proteins seem to be involved in the antinociceptive effect of various agents, including ␣ 2 agonists, 28 baclofen, and noradrenaline. 51 Furthermore, there is experimental evidence of a possible interaction between A 1 R and PTX-resistant stimulatory Gs proteins or inhibitory Gz proteins. 52, 53 However, the role of PTX-insensitive G proteins for A 1 R-induced antinociception in the spinal cord is not clear. In in vitro experiments, Cordeaux et al. 52, 53 demonstrated that after an increased expression of A 1 Rs, the application of different A 1 R agonists (NECA Ͼ Ͼ CPA ϭ R-PIA) caused an accumulation of cAMP mediated by PTX-insensitive G proteins. If this pathway occurs in the spinal cord, we would expect that the intrathecal administration of an A 1 R agonist in PTX-pretreated animals causes pain behaviors due to inhibition of adenylate cyclase and subsequently an accumulation of cAMP. In contrast, in the current study, the R-PIA-induced antinociceptive effect was largely blocked by PTX pretreatment without producing increased pain behaviors, suggesting an interaction between A 1 R and PTX-sensitive Gi proteins but not PTX-insensitive Gs or Gq proteins. However, a pronociceptive effect mediated by PTX-resistant Gs or Gq proteins using higher doses of R-PIA, other A 1 R agonists, or a different animal pain model cannot be discarded.
Among various Gi proteins, Gz is the only member of this subfamily with a PTX-resistant ␣ z subunit. 54 The PTX-resistant Gz protein is located predominantly in the central nervous system and retina and interacts with several Gi-coupled receptors, including A 1 R and opioid receptors. 55 To date, the only known signaling function of Gz is inhibition of adenylyl cyclase. Although a role of Gz proteins for A 1 R-induced antinociception cannot be discarded, we demonstrated that a blockade of PTXsensitive G protein receptors prevented completely the antinociceptive effect of R-PIA, speculating that the PTXresistant G protein receptor Gz will be of limited importance for A 1 R-mediated antihyperalgesia. Although similar results were obtained for normal nociception in uninjured animals by using the tail flick and hot plate tests, 30 results of the current study demonstrate for the first time that A 1 R-induced spinal antinociception after an incision is mediated by interactions with PTX-sensitive G proteins and due to the inhibition of adenylate cyclase.
Possible Mechanisms of A 1 R-induced Antinociception: Interaction with Potassium Channels
There is ample evidence that potassium channels are involved in nociception and that the opening of specific potassium channels is critical for G protein-coupled receptor-mediated antinociception including opioid receptors, ␥-aminobutyric acid type B receptors, ␣ 2 receptors, and A 1 Rs. 8, 56 Ocana and Baeyens 57 revealed in uninjured animals that different intracerebroventricularly administered K ATP channel blockers antagonized A 1 R-induced supraspinal antinociception. In the current study, we assessed for the first time the importance of different potassium channels for A 1 R-mediated antinociception in animals after a tissue injury (incision). In agreement with Ocana et al., 57 we demonstrated that R-PIA-induced hypoalgesia was attenuated by intrathecal administration of a K ATP channel blocker. Similarly, intrathecal administration of the nonselective potassium channel blockers tetraethylammonium and 4-AP decreased the antinociceptive effect of R-PIA on incisional pain, indicating a possible role of other potassium channels for A 1 R-induced hypoalgesia.
Calcium-activated potassium channels are subdivided in small (SK), intermediate (IK), or large (BK) conductance channels and are activated by an increased intracellular calcium concentration. The bee venom toxin apamin (high-affinity SK channel inhibitor; Ki: 60 pM-100 nM) 58 and the scorpion toxin charybdotoxin (IK, BK inhibitor; Ki: 1.7-5 nM) 59 have been used to demonstrate that spinal SK channels seem to be involved in antinociception mediated by cannabinoid and ␦-opioid receptors. 60, 61 In the current study, the intrathecal application of neither apamin nor charybdotoxin modified R-PIAinduced hypoalgesia, indicating that calcium-activated potassium channels are not involved in A 1 R-mediated antinociception.
Besides its effects on BK and IK conductance channels, charybdotoxin inhibits also the voltage-gated potassium channel Kv1.3 (Ki: 0.17 nM). 62 Margatoxin blocks Kv1.3 and Kv1.6 (Ki: 0.03 and 5 nM) but not calcium-activated potassium channels. 59, 62 Both scorpion toxins have been used to demonstrate that Kv1 channels are important for ␣ 2 -adrenoceptor-, -opioid receptor-, 56 and nonsteroidal antiinflammatory drug 31 -induced antinociception. In the current, study neither charybdotoxin nor margatoxin decreased R-PIA-induced hypoalgesia, indicating that Kv1.3 and Kv1.6 channels are not involved in A 1 Rmediated antinociception.
Therefore, the opening of K ATP but not of calciumactivated potassium channels and of Kv1.3 and 1.6 channels is important for antinociception mediated by A 1 R agonists. The role of other potassium channels for A 1 Rinduced antinociception must be clarified.
Conclusion
In the current study, we demonstrated that the intrathecal administration of an adenosine A 1 R agonist (R-PIA) but not of an adenosine A 2a R agonist (CGS21680) decreased mechanical hyperalgesia after a surgical incision. Furthermore, A 1 R-induced spinal antinociception is mediated by interactions with PTX-sensitive G proteins and due to the inhibition of adenylate cyclase. The opening of K ATP channels but not of calcium-activated potassium channels or the voltage-gated channels Kv1.3 and Kv1.6 may contribute to the antinociceptive effect of A 1 R agonists.
